Story
BlossomHill Therapeutics Stock Gains on Positive Lung Cancer Drug Data
BlossomHill Therapeutics (NASDAQ: BLSM) saw its stock surge in pre-market trading on Tuesday after the company announced positive updated data from a clinical trial for its experimental lung cancer drug, BH-30643. The company presented the findings at the 2026 World Conference on Lung Cancer in Seoul, South Korea.
SOLARA Trial Shows High Response Rate
The Phase 1/2 SOLARA trial evaluated BH-30643 in 40 patients with a specific treatment-resistant form of cancer known as EGFR C797S-positive non-small cell lung cancer (NSCLC). According to the company's presentation, this is a patient population for which no approved oral targeted therapies currently exist.
The updated results demonstrated significant efficacy in this difficult-to-treat setting:
- An objective response rate (ORR) of 45% was observed.
- The disease control rate (DCR) reached 88%.
- At a median follow-up of nearly seven months, 63% of patients remained on the treatment, suggesting a durable response.
Investor Visibility and Analyst Support
AdThe positive clinical readout coincided with other key events, amplifying investor interest. BlossomHill CEO J. Jean Cui presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York on the same day, putting the trial results directly in front of an institutional audience.
This follows a recent initiation of coverage by Guggenheim on September 1, where the firm assigned a Buy rating and a $30 price target to BLSM stock. The drug, BH-30643, also holds an FDA Fast Track designation, which underscores the significant unmet medical need it aims to address.
Market Performance
BlossomHill's pre-market gain of 4.4% stood in contrast to the broader market, with major indices like the S&P 500 and NASDAQ trading slightly lower, according to market data. This indicates the rally was driven by company-specific news rather than a wider market trend.
The stock, which went public in August 2026 at an IPO price of $16.00 per share, has performed well and is now trading near its 52-week high of $23.37.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.